Cytomegalovirus (CMV) Serostatus Reassessment in CMV Seronegative Kidney Transplant Candidates
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.70150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Ajmeet K Pama-Ghuman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Cytomegalovirus Infections, Cytomegalovirus. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Background
Recipient cytomegalovirus (CMV) serostatus reassessment proximate to transplant for initially CMV seronegative patients is critical to guide post‐transplant CMV preventive strategies in kidney transplant recipients (KTR), since seroconversion during the long wait‐list time could lead to CMV serostatus misclassification. The feasibility and optimal timing of CMV serostatus reassessment and the incidence of seroconversion have not been systematically examined.
Methods
Program adherence to a guideline for CMV serology reassessment within 6 months of transplant among initially CMV seronegative adults undergoing a first kidney transplant between December 17, 2022 and December 17, 2024 was retrospectively assessed. The association of baseline and transplant factors with adherence was compared by chi‐square or Fisher's exact test ( p < 0.05 considered significant). The incidence of CMV seroconversion between the time of listing and transplant was calculated per person‐years of follow‐up.
Results
Among 823 adult KTR, 586 (71.2%) were eligible and 127 (21.7%) were CMV seronegative at listing. The median (interquartile range) time to transplant was longer for deceased (5.23 [2.86–7.44] years) than living donor KTR (1.51 [0.76–2.74] years). Program adherence was 91.3% (116/127) overall and higher among living (65/65 [100%]) versus deceased donor transplants (51/62 [82.3%]), p < 0.01). No demographic or transplant‐related variables were associated with adherence ( p > 0.05 for all variables). Seroconversion between listing and transplant occurred in two of 124 patients (1.6%), an incidence of 0.0043 per person‐year of follow‐up.
Conclusion
Program adherence to CMV serostatus reassessment within 6 months of transplant was high in a clinical setting and identified a low incidence of seroconversion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
- Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
- Department of Surgery, University of California, San Francisco, San Francisco, California, USA.
- Transplant Quality, University of California, San Francisco, San Francisco, California, USA.
ORCID-Profile: Ajmeet K Pama-Ghuman, Puneet Sood, Monica Fung, Garrett R Roll, Anna Mello, Lakshin Kumar, Ajit P Limaye
Zitieren
APA
Pama-Ghuman, A. K., Sood, P., Fung, M., Roll, G. R., Mello, A., Kumar, L., & Limaye, A. P. (2025). Cytomegalovirus (CMV) Serostatus Reassessment in CMV Seronegative Kidney Transplant Candidates. Transplant Infectious Disease. https://doi.org/10.1111/tid.70150
Vancouver
Pama-Ghuman AK, Sood P, Fung M, Roll GR, Mello A, Kumar L, et al. Cytomegalovirus (CMV) Serostatus Reassessment in CMV Seronegative Kidney Transplant Candidates. Transplant Infectious Disease. 2025. doi:10.1111/tid.70150
BibTeX
@article{PamaGhuman2025,
author = {Pama-Ghuman, Ajmeet K and Sood, Puneet and Fung, Monica and Roll, Garrett R and Mello, Anna and Kumar, Lakshin and Limaye, Ajit P},
title = {Cytomegalovirus (CMV) Serostatus Reassessment in CMV Seronegative Kidney Transplant Candidates},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.70150}
}
EUVIMED